2014 ACR/ARHP Annual Meeting

November 14-19, 2014. Boston, MA.

View by Title View Sessions

Jump to: View All • a b c d e f g h i j k l m n o p q r s t u v [w] x y z

Abstract Number: 1391

Weight Loss and Risk of Death in Rheumatoid Arthritis
Abstract Number: 1385

What Discriminates Best Flares in Rheumatoid Arthritis (RA)? a Subanalysis of the Strass Treatment Tapering in RA Study
Abstract Number: 2011

What Do State Legislators Think about Arthritis? Results of Focus Groups with State Legislators
Abstract Number: 58

What Does the Patient Global Assessment Mean for Patients with Psoriatic Arthritis? A Post-Hoc Analysis of 223 Patients with Psoriatic Arthritis
Abstract Number: 2132

What Is Associated with X- Ray Progression at 5 Years in Rheumatoid Arthritis (RA) Patients in Low Disease Activity?
Abstract Number: 382

What Is More Predictive of Achieving Remission at 12 Months: The Percentage of Baseline Improvement or the Actual Disease State Achieved at 6 Months?
Abstract Number: 583

What Is the Correlation of Individual HAQ and Basdai Questions with Disease Activity Measures in Ankylosing Spondylitis? Implications for Instrument Reduction
Abstract Number: 1071

What Is the Impact of Chronic Systemic Inflammation Such As Rheumatoid Arthritis on Mortality Following Cancer?
Abstract Number: 2518

What Is the Level of Agreement Between Disease Activity Indices and Response Criteria Among Rheumatoid Arthritis Patients Treated with TNF Inhibitors?
Abstract Number: 379

What Level of Disease Activity at 6 Months Predicts Achieving or Sustaining Remission at 12 Months?
Abstract Number: 2588

Which Characteristics of Inflammatory Back Pain (CBP) Forecast the Presence of HLA-B27? Results from the Esperanza Cohort
Abstract Number: 2586

Which Characteristics of Inflammatory Back Pain (CBP) Forecast the Presence of Sacroiliitis on Magnetic Resonance Imaging (MRI)? Results from the Esperanza Cohort
Abstract Number: 2481

Which Factors Influence the Prescription of Tocilizumab Alone or in Combination with DMARDsÂ in Rheumatoid Arthritis Patients in a Real Life Setting?: An Interim Analysis of Safety and Efficacy at 6 Months
Abstract Number: 1099

Which Stresses Bother Fibromyalgia Patients Most?
Abstract Number: 522

Whole Blood microRNA Signature for Primary Sjögren’s Syndrome-Related Lymphoma
Abstract Number: 83

Whole Exome Sequencing Analysis Performed on a Patient with Fibroblastic Rheumatism
Abstract Number: 2773

Whole-Body MRI Reveals Characteristic Extracapsular Pattern of Inflammation in Polymyalgia Rheumatica
Abstract Number: 2437

Why Doesn’t Participation in Activity Increase Following Hip or Knee Replacement?
Abstract Number: 2774

Why Leg Ulcers Do Not Heal? a Prospective Study Showing High Proportion of Small Vessel Vasculitis
Abstract Number: 1905

Within-Day Variation and Influence of Physical Exercise on Circulating Galectin-3 in Patients with Rheumatoid Arthritis and Healthy Individuals
Abstract Number: 242

WOMAC Pain Score Reflects Preceding Daily Pain Ratings in Knee Osteoarthritis Interventional Randomized Clinical Trials
Abstract Number: 1094

Work Productivity and Healthcare Utilization in Patients with Fibromyalgia and Comorbid Depression Taking Antidepressant Medication
Abstract Number: 1597

Work Productivity Improvement Associated with Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Results of a Phase 3, Randomized, Controlled Trial
Abstract Number: 2625

Work Productivity in Systemic Lupus Erythematosus: Relationship with Clinical Features
Abstract Number: 1057

Work-Related Behavior and Experiences in Patients with Rheumatoid Arthritis
Abstract Number: 1078

Work-Related Behavior and Experiences in Patients with Systemic Lupus Erythematosus
Abstract Number: 2410

Working Status and Improvements in Work Productivity over Time in an Early Rheumatoid Arthritis (ERA) Cohort

Jump to: View All • a b c d e f g h i j k l m n o p q r s t u v [w] x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].